Skip to main content
. 2021 Jan 5;3(2):fcaa233. doi: 10.1093/braincomms/fcaa233

Table 1.

Demographic characteristics and clinical presentation of 144 patients referred for possible HE/SREAT diagnosis

Autoimmune CNS disorder (n = 39) Alternative diagnosis (n = 105) Total (n = 144) P value
Female 24 (61.5) 79 (75.2) 103 (71.5) 0.15
Median age (years) at onset (range) 46.0 (13–87) 44.0 (10–81) 44.5 (10–87) 0.08
Median duration (months) of symptoms (range) 16 (2–187) 30 (1–414) 25 (1–414) 0.02
Sub-acute onset (<3 months) 32 (82.1) 29 (27.6) 61 (42.4) <0.001
Fluctuating course 23 (59) 46 (43.8) 69 (47.9) 0.13
History of autoimmune thyroid disease 24 (61.5) 78 (74.3) 102 (70.8) 0.15
Co-existing autoimmune disorder 13 (33.3) 17 (16.2) 30 (20.8) 0.04
Past history of neoplasm 4 (10.3) 5 (4.8) 9 (6.3) 0.25
Family history of autoimmune disorder 22 (56.4) 39 (37.1) 61 (42.4) 0.06
Prior immunotherapy 35 (89.7) 79 (75.2) 114 (79.2) 0.07
Reported immunotherapy response 33 (94.3) 29 (36.3) 62 (53.9) <0.001
Clinical presentation
Cognitive complaint 37 (94.9) 94 (89.5) 131 (91) 0.51
Seizures 10 (25.6) 8 (7.6) 18 (12.5) 0.008
Stroke-like episodes 8 (20.5) 5 (4.8) 13 (9) 0.007
Language deficit 11 (28.2) 13 (12.4) 24 (16.7) 0.04
Ataxia 6 (15.4) 4 (3.8) 10 (6.9) 0.02
Apraxia 3 (7.7) 7 (6.7) 10 (6.9) >0.99
Motor or sensory deficits 15 (38.5) 22 (21) 37 (25.7) 0.05
Tremor 8 (20.5) 11 (10.5) 19 (13.2) 0.16
Myoclonus 2 (5.1) 5 (4.8) 7 (4.9) >0.99
Hypersomnolence 5 (12.8) 17 (16.2) 22 (15.3) 0.8
Psychosis 13 (33.3) 21 (20) 34 (23.6) 0.12
Headache 9 (23.1) 27 (25.7) 36 (25) 0.83
Depression 5 (12.8) 37 (35.2) 42 (29.2) 0.008
Anxiety 1 (2.6) 25 (23.8) 26 (18.1) 0.003
Chronic pain 2 (5.1) 31 (29.5) 33 (22.9) 0.002

Categorical data provided as number (percentage). Bold values denote statistically significant results (P < 0.05).